NIJMEGEN, the Netherlands, November 2, 2022 — Enzyre, which is developing ground-breaking ambulant diagnostic technology for blood coagulation testing, announced today that it had raised EUR 12 million in a Series A financing led by new investor Oost NL, with participation from i&i Biotech Fund, Demcon Investment as a technology partner, and existing investors Takeda Ventures and Novalis Biotech. The Dutch government’s Innovation Credit contributes to the funding.

The funding will allow Enzyre to continue developing its unique diagnostic technology platform, EnzyPad, which will enable people living with hemophilia to diagnose and monitor their coagulation status in real-time from home. The cash will assist clinical trial registrations, the construction of a sustainable manufacturing line, and investment in expanding critical care applications.

Enzyre’s Chief Executive Officer, Guido Maertens, stated: 

“We are thrilled to have completed this successful fundraising round, which confirms our technology and will support our continuous development as we move Enzyre into the next growth phase. We appreciate Takeda’s sustained support and the dedication of a strong group of new and current investors. We look forward to working together to improve the quality of life for individuals living with bleeding disorders by advancing our aim of transforming their standard of treatment.”

Pieter Rhemrev, senior investment manager at Oost NL and the syndicate’s principal investor, stated: 

“We are thrilled to be collaborating with Enzyre on the development of a revolutionary technology that has the potential to alter the way Hemophilia A and other bleeding diseases are managed. The ability of clinicians to monitor coagulation status in real-time will significantly improve patient outcomes and quality of life, and we see huge potential for the device to enhance tailored treatment. We look forward to supporting Enzyre’s future development with this excellent team and our syndicate partners.”

More about the startup:

Waander van Heerde and Guido Maertens launched Enzyre as a spin-off from Radboud University Medical Center in the Netherlands. The Company’s goal is to create diagnostic equipment that would allow patients to evaluate their coagulation status no matter where they are. Enzyre’s platform takes only a tiny amount of blood to test up to sixteen responses concurrently with excellent sensitivity and specificity, whether at home, on the road, or in a critical care scenario.

Hemophilia was Enzyre’s first product. EnzyCard employs the Company’s unique EnzyPad platform technology to assess the coagulation status of individuals suffering from hemophilia, a rare genetic condition that affects an estimated 800,000 people globally. 

We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! 

Next Article

Previous articleWhat is DevOps Outsourcing Services
Next articleMunich-based platform startup Flowers Software raises USD 3.2 million in seed funding
Kshitij does business research and content writing for VCBay. Pursuing BBA from Symbiosis Center Of Management Studies (SCMS) Pune, he is skilled in Financial Modeling, Stock valuation and Microsoft Excel. He is passionate about Entrepreneurship and Finance.


Please enter your comment!
Please enter your name here